STOCKSCOUTER

StockScouter Premium

StockScouter Screener and Portfolios are now in our premium offering.
Learn more or Get it now! Stockscouter Portfolio performance

NLTX NEOLEUKIN THERAPEUTICS INCORPORATED StockScouter® Report

9

StockScouter® Score

NEOLEUKIN THERAPEUTICS INCORPORATED, a micro cap company in the healthcare sector, is expected to outperform the market over the next six months with average risk

10 is the best possible rating. Learn more.

Summary

Positives

  • Earnings growth in the past year has accelerated rapidly compared to earnings growth in the past three years. Positive
  • The multi-period measure of relative price change and consistency is above average. Positive/Neutral
  • Moving average analysis for NLTX suggests flat price movement over the medium term. Neutral

 

Concerns

  • Short-term relative price momentum exhibits meaningful weakness. Negative

 

Short-term Outlook

Over the next 1-2 months, StockScouter forecasts that micro cap stocks will be in favor, stocks will be , and healthcare stocks will be in favor.

Expected Risk/Return

Progress: 60% done.
Progress: 100% done.
Low
High

Core Model Grades

B
C
N/A
B

Previous Ratings

9